A Barney Hawthorne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
A Barney Hawthorne has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
G. T. Williams
Pathology
2 shared publicationsJared Torkington
2 shared publicationsJoanna Hurley
2 shared publicationsJohn Green
2 shared publications- Sunil Dolwani
Division of Population Medicine, Cardiff University School of Medicine, Cardiff, UK
2 shared publications A. Roberts
Radiology, University Hospital of Wales, Cardiff, UK
1 shared publication
Latest Publications
- Open Access
PWE-040 Prevalent Round Stage Shift in the National Bowel Cancer Screening Programme in Wales; Data from the First 3 Years at a Single Screening Centre: Abstract PWE-040 Table 1
Introduction Colorectal cancer screening is based on early detection of cancers and removal of premalignant polyps though this adenoma to carcinoma sequence is thought to progress over several years. The Bowel Screening Programme in Wales based on guaiac FOBt and colonoscopy for individuals resting positive began roll-out in October 2008, with the aim of reducing mortality through cancer detection at an early stage. The aim of this study was to investigate whether screen detected cancers in Cardiff and the Vale of Glamorgan demonstrated any shift in the stage of cancer during the first three years of screening (initial prevalent round). Methods Data was collected prospectively to compare the staging of colorectal cancer diagnosed in the BCSP with cancers diagnosed in the non-screening population in the same geographical region from 1st October 2008 to 31st December 2011. All information was cross checked with Cancer Registry data. Results Screen detected cancer was found in 69 individuals (44 male, 25 female), with a positive predictive value of colonoscopy (after positive FOB testing) of 8.7%. Complete clinical staging was available for all 69 individuals; two patients did not undergo surgical resection due to the presence of metastases after radiological staging. There were 696 non-screening detected cancers during the same time period. For the purposes of this analysis, polyp cancers (cancer that was removed by endoscopic means at the time of colonoscopy/flexible sigmoidoscopy) were included in Duke’s stage A, except for one polyp cancer that required subsequent surgical resection and was staged as Duke’s C1. The results are shown in table 1. Three-quarters of cancers diagnosed in the BCSP were Dukes A or B, compared to 44.1% in the non-screening population. Of Duke’s D cancers, only 2.8% were diagnosed through screening, with 27% diagnosed in the non screening population (p < 0.0001). Stage of cancer diagnosed with comparable data from non-screening population Conclusion This data strongly supports significant stage shift of colorectal cancer even within the initial prevalent round in this single Bowel Cancer Screening centre in Wales that the benefits of screening may be demonstrable in outcomes at a relatively early stage of the programme. Disclosure of Interest None Declared.
Open AccessPWE-040 Prevalent Round Stage Shift in the National Bowel Cancer Screening Programme in Wales; Data from the First 3 Years at a Single Screening Centre: Abstract PWE-040 Table 1
Introduction Colorectal cancer screening is based on early detection of cancers and removal of premalignant polyps though this adenoma to carcinoma sequence is thought to progress over several years. The Bowel Screening Programme in Wales based on guaiac FOBt and colonoscopy for individuals resting positive began roll-out in October 2008, with the aim of reducing mortality through cancer detection at an early stage. The aim of this study was to investigate whether screen detected cancers in Cardiff and the Vale of Glamorgan demonstrated any shift in the stage of cancer during the first three years of screening (initial prevalent round). Methods Data was collected prospectively to compare the staging of colorectal cancer diagnosed in the BCSP with cancers diagnosed in the non-screening population in the same geographical region from 1st October 2008 to 31st December 2011. All information was cross checked with Cancer Registry data. Results Screen detected cancer was found in 69 individuals (44 male, 25 female), with a positive predictive value of colonoscopy (after positive FOB testing) of 8.7%. Complete clinical staging was available for all 69 individuals; two patients did not undergo surgical resection due to the presence of metastases after radiological staging. There were 696 non-screening detected cancers during the same time period. For the purposes of this analysis, polyp cancers (cancer that was removed by endoscopic means at the time of colonoscopy/flexible sigmoidoscopy) were included in Duke’s stage A, except for one polyp cancer that required subsequent surgical resection and was staged as Duke’s C1. The results are shown in table 1. Three-quarters of cancers diagnosed in the BCSP were Dukes A or B, compared to 44.1% in the non-screening population. Of Duke’s D cancers, only 2.8% were diagnosed through screening, with 27% diagnosed in the non screening population (p < 0.0001). Stage of cancer diagnosed with comparable data from non-screening population Conclusion This data strongly supports significant stage shift of colorectal cancer even within the initial prevalent round in this single Bowel Cancer Screening centre in Wales that the benefits of screening may be demonstrable in outcomes at a relatively early stage of the programme. Disclosure of Interest None Declared.
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo1195 The Management of Large Sessile Colorectal Polyps: Experience of a Single Welsh Screening Centre
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo1195 The Management of Large Sessile Colorectal Polyps: Experience of a Single Welsh Screening Centre
- 1 April 2010
- Published by BMJ in Frontline Gastroenterology
- Vol. 1 (1) , 44-51
Optimising use of thiopurines in inflammatory bowel disease
Azathioprine (AZA) and 6-mercaptopurine (6-MP) are the most widely used immunosuppressive therapies in inflammatory bowel disease. Pretreatment measurement of thiopurine methyltransferase (TPMT) activity is recommended and although conventional practice is to use a dose of 2 mg/kg AZA (1 mg/kg 6-MP), higher doses of 2.5 mg/kg AZA or more may be required in some patients, particularly if TPMT activity is high. Dose raising is limited by toxicity, and a robust monitoring system is mandatory. Patients with side effects to AZA may tolerate 6-MP but pancreatitis is a contraindication to switching. Metabolite monitoring is not widely available but may be useful, particularly if non-compliance is possible or where metabolite shunting to 6-methylmercaptopurine is suspected, on the basis of non-response or toxicity. It may allow dose optimisation before switching to alternative immunosuppressants. The drug appears safe in pregnancy and breast feeding. Long term duration of therapy is a balance between benefits in relation to the underlying disease extent, activity and aggressiveness, and the risk of neoplasia, particularly lymphoma.
- 1 April 2010
- Published by BMJ in Frontline Gastroenterology
- Vol. 1 (1) , 44-51
Optimising use of thiopurines in inflammatory bowel disease
Azathioprine (AZA) and 6-mercaptopurine (6-MP) are the most widely used immunosuppressive therapies in inflammatory bowel disease. Pretreatment measurement of thiopurine methyltransferase (TPMT) activity is recommended and although conventional practice is to use a dose of 2 mg/kg AZA (1 mg/kg 6-MP), higher doses of 2.5 mg/kg AZA or more may be required in some patients, particularly if TPMT activity is high. Dose raising is limited by toxicity, and a robust monitoring system is mandatory. Patients with side effects to AZA may tolerate 6-MP but pancreatitis is a contraindication to switching. Metabolite monitoring is not widely available but may be useful, particularly if non-compliance is possible or where metabolite shunting to 6-methylmercaptopurine is suspected, on the basis of non-response or toxicity. It may allow dose optimisation before switching to alternative immunosuppressants. The drug appears safe in pregnancy and breast feeding. Long term duration of therapy is a balance between benefits in relation to the underlying disease extent, activity and aggressiveness, and the risk of neoplasia, particularly lymphoma.
- 31 March 2008
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (12) , 1157-1166
Review article: medication non‐adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies
Summary: Background Significant number of patients with ulcerative colitis (UC) fail to comply with treatment.Aims To review issues surrounding medication non‐adherence in inflammatory bowel disease (IBD), including the clinical and health service implications in the UK, and discuss strategies for optimizing medication adherence.Methods Articles cited were identified via a PubMed search, utilizing the words IBD, adherence, compliance, medication and UC.Results Medication non‐adherence is multifactorial involving factors other than dosing frequency. Male gender (OR: 2.06), new patient status (OR: 2.14), work and travel pressures (OR: 4.9) and shorter disease duration (OR: 2.1), among others are proven predictors of non‐adherence in UC. These indicators can identify ‘at‐risk’ patients and allow an individually tailored treatment approach to be introduced that optimizes medication adherence. A collaborative relationship between physician and patient is important; several strategies for improving adherence have been proven effective including open dialogue that takes into consideration the patient’s health beliefs and concerns, providing educational (e.g. verbal/written information, self‐management programmes) and behavioural interventions (e.g. calendar blister packs, cues/reminders).Conclusions Educational and behavioural interventions tailored to individual patients can optimize medication adherence. Additional studies combining educational and behavioural interventions may provide further strategies for improving medication adherence rates in UC.
- 31 March 2008
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (12) , 1157-1166
Review article: medication non‐adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies
Summary: Background Significant number of patients with ulcerative colitis (UC) fail to comply with treatment.Aims To review issues surrounding medication non‐adherence in inflammatory bowel disease (IBD), including the clinical and health service implications in the UK, and discuss strategies for optimizing medication adherence.Methods Articles cited were identified via a PubMed search, utilizing the words IBD, adherence, compliance, medication and UC.Results Medication non‐adherence is multifactorial involving factors other than dosing frequency. Male gender (OR: 2.06), new patient status (OR: 2.14), work and travel pressures (OR: 4.9) and shorter disease duration (OR: 2.1), among others are proven predictors of non‐adherence in UC. These indicators can identify ‘at‐risk’ patients and allow an individually tailored treatment approach to be introduced that optimizes medication adherence. A collaborative relationship between physician and patient is important; several strategies for improving adherence have been proven effective including open dialogue that takes into consideration the patient’s health beliefs and concerns, providing educational (e.g. verbal/written information, self‐management programmes) and behavioural interventions (e.g. calendar blister packs, cues/reminders).Conclusions Educational and behavioural interventions tailored to individual patients can optimize medication adherence. Additional studies combining educational and behavioural interventions may provide further strategies for improving medication adherence rates in UC.
- Open Access
- 14 November 2007
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (3) , 211-219
The incidence of Crohn’s disease in Cardiff over the last 75 years: an update for 1996–2005
Summary: Background The incidence of Crohn's disease rose rapidly in industralized countries over the past 50 years, but it is unclear whether the incidence is still rising or has reached a plateau.Aims To update the long‐term incidence study of Crohn’s disease in Cardiff for 1996–2005, to investigate whether incidence is still rising and to study changes in disease characteristics over time.Method Crohn’s cases identified by retrospective analysis of hospital records as in previous studies in Cardiff.Results Two hundred and twelve cases were identified. Corrected incidence for this decade was 66 × 106 per year (95% confidence interval: 58–76), showing a continuing rise compared to previous decades. The proportion with colonic disease at presentation continues to rise (43%) with a corresponding fall in those with terminal ileal disease. There remains a strong female preponderance (F:M 1.6:1) as in previous studies. The incidence in children under age 16 continues to rise, and the median age at diagnosis has fallen slightly.Conclusion Crohn’s disease incidence continues to rise slowly in Cardiff with a continuing increase in those presenting with colonic disease, which is now the commonest disease pattern.
- 14 November 2007
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (3) , 211-219
Open AccessThe incidence of Crohn’s disease in Cardiff over the last 75 years: an update for 1996–2005
Summary: Background The incidence of Crohn's disease rose rapidly in industralized countries over the past 50 years, but it is unclear whether the incidence is still rising or has reached a plateau.Aims To update the long‐term incidence study of Crohn’s disease in Cardiff for 1996–2005, to investigate whether incidence is still rising and to study changes in disease characteristics over time.Method Crohn’s cases identified by retrospective analysis of hospital records as in previous studies in Cardiff.Results Two hundred and twelve cases were identified. Corrected incidence for this decade was 66 × 106 per year (95% confidence interval: 58–76), showing a continuing rise compared to previous decades. The proportion with colonic disease at presentation continues to rise (43%) with a corresponding fall in those with terminal ileal disease. There remains a strong female preponderance (F:M 1.6:1) as in previous studies. The incidence in children under age 16 continues to rise, and the median age at diagnosis has fallen slightly.Conclusion Crohn’s disease incidence continues to rise slowly in Cardiff with a continuing increase in those presenting with colonic disease, which is now the commonest disease pattern.
- 21 October 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (10) , 907-916
Review article: how and when to use ciclosporin in ulcerative colitis
Summary: Although colectomy for ulcerative colitis is curative, long‐term quality of life is reduced.Intravenous ciclosporin 4 mg/kg/day has significant toxicity. There is now evidence that low‐dose ciclosporin (2 mg/kg daily by intravenous infusion, or 5–6 mg/kg daily in a twice daily oral dosage) has an acceptable safety profile, even when used in combination with corticosteroids. Drug dosage should be adjusted to the levels of 150–250 ng/mL initially (random levels during intravenous infusion, or trough levels for oral use).Ciclosporin should be considered not only in those who have failed 7 days of corticosteroids, but also in fulminant colitis at day 3, if not responding to corticosteroids. The drug should be avoided in frail or elderly patients with significant comorbidity, and also where colectomy is likely to be necessary in the short to medium term. Ciclosporin should not be continued for more than 7 days, unless there is a definite response.A 70–80% initial response is likely, and responders are discharged on oral ciclosporin, adding thiopurines and tailing prednisolone rapidly. The drug should be continued for 3 months. The likelihood of avoiding colectomy over 2–3 years is 40–50%.More studies are needed to evaluate the use of oral ciclosporin in corticosteroid‐refractory colitis in out‐patients, and to assess whether monotherapy (without corticosteroids) is significantly safer, without loss of efficacy.
- 21 October 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (10) , 907-916
Review article: how and when to use ciclosporin in ulcerative colitis
Summary: Although colectomy for ulcerative colitis is curative, long‐term quality of life is reduced.Intravenous ciclosporin 4 mg/kg/day has significant toxicity. There is now evidence that low‐dose ciclosporin (2 mg/kg daily by intravenous infusion, or 5–6 mg/kg daily in a twice daily oral dosage) has an acceptable safety profile, even when used in combination with corticosteroids. Drug dosage should be adjusted to the levels of 150–250 ng/mL initially (random levels during intravenous infusion, or trough levels for oral use).Ciclosporin should be considered not only in those who have failed 7 days of corticosteroids, but also in fulminant colitis at day 3, if not responding to corticosteroids. The drug should be avoided in frail or elderly patients with significant comorbidity, and also where colectomy is likely to be necessary in the short to medium term. Ciclosporin should not be continued for more than 7 days, unless there is a definite response.A 70–80% initial response is likely, and responders are discharged on oral ciclosporin, adding thiopurines and tailing prednisolone rapidly. The drug should be continued for 3 months. The likelihood of avoiding colectomy over 2–3 years is 40–50%.More studies are needed to evaluate the use of oral ciclosporin in corticosteroid‐refractory colitis in out‐patients, and to assess whether monotherapy (without corticosteroids) is significantly safer, without loss of efficacy.
- 1 September 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (6) , 615-621
Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology
Summary: Backgound : Patients being investigated for symptoms of abdominal pain, diarrhoea and or weight loss often undergo small bowel radiology as part of their diagnostic workup mainly to exclude inflammatory bowel disease.Aim : To assess and compare the utility of a single faecal calprotectin estimation to barium follow through as well as conventional inflammatory markers such as erythrocyte sedimentation rate and C‐reactive protein in exclusion of intestinal inflammation.Methods : Seventy‐three consecutive cases undergoing barium follow through for investigation of symptoms of diarrhoea and or abdominal pain with or without weight loss were studied. The control group comprised 25 cases with known active Crohn's disease (positive controls), 26 normal healthy volunteers (negative controls) and 25 cases of irritable bowel syndrome diagnosed by Rome II criteria. Symptoms, erythrocyte sedimentation rate and C‐reactive protein were recorded at recruitment and a single stool sample assayed for calprotectin within 7 days prior to or after barium follow through.Results : The median calprotectin value in the active Crohn's group, irritable bowel syndrome group and normal volunteers was 227 μg/g of stool, 19 and 10 μg/g respectively (P < 0.0001). A faecal calprotectin above a cut‐off value of 60 μg/g was able to predict all nine cases with an abnormal barium follow through as well as all six cases with a normal barium follow through but with organic intestinal disease. The negative predictive value of a single calprotectin result below 60 μg/g of stool was 100% compared with 91% each for erythrocyte sedimentation rate > 10 mm and C‐reactive protein > 6 mg/L and 84% for a combination of erythrocyte sedimentation rate and C‐reactive protein in predicting absence of organic intestinal disease.Conclusion : A single stool calprotectin value < 60 μg/g of stool obviates the need for further barium radiology of the small bowel, is more accurate than measurement of erythrocyte sedimentation rate or C‐reactive protein and effectively excludes Crohn's disease or non‐functional gastrointestinal disease.
- 1 September 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (6) , 615-621
Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology
Summary: Backgound : Patients being investigated for symptoms of abdominal pain, diarrhoea and or weight loss often undergo small bowel radiology as part of their diagnostic workup mainly to exclude inflammatory bowel disease.Aim : To assess and compare the utility of a single faecal calprotectin estimation to barium follow through as well as conventional inflammatory markers such as erythrocyte sedimentation rate and C‐reactive protein in exclusion of intestinal inflammation.Methods : Seventy‐three consecutive cases undergoing barium follow through for investigation of symptoms of diarrhoea and or abdominal pain with or without weight loss were studied. The control group comprised 25 cases with known active Crohn's disease (positive controls), 26 normal healthy volunteers (negative controls) and 25 cases of irritable bowel syndrome diagnosed by Rome II criteria. Symptoms, erythrocyte sedimentation rate and C‐reactive protein were recorded at recruitment and a single stool sample assayed for calprotectin within 7 days prior to or after barium follow through.Results : The median calprotectin value in the active Crohn's group, irritable bowel syndrome group and normal volunteers was 227 μg/g of stool, 19 and 10 μg/g respectively (P < 0.0001). A faecal calprotectin above a cut‐off value of 60 μg/g was able to predict all nine cases with an abnormal barium follow through as well as all six cases with a normal barium follow through but with organic intestinal disease. The negative predictive value of a single calprotectin result below 60 μg/g of stool was 100% compared with 91% each for erythrocyte sedimentation rate > 10 mm and C‐reactive protein > 6 mg/L and 84% for a combination of erythrocyte sedimentation rate and C‐reactive protein in predicting absence of organic intestinal disease.Conclusion : A single stool calprotectin value < 60 μg/g of stool obviates the need for further barium radiology of the small bowel, is more accurate than measurement of erythrocyte sedimentation rate or C‐reactive protein and effectively excludes Crohn's disease or non‐functional gastrointestinal disease.
- 1 September 2004
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 36 (9) , 834
Endoscopic Clipping of a Nonhealing Gastrocutaneous Fistula Following Gastrostomy Removal
A 67-year-old lady with anorexia had a percutaneous endoscopic gastrostomy (PEG) tube for long-term feeding. She also suffered from psoriasis. After 5 years the PEG was removed, but a month later she presented at the hospital with a productive cough and symptoms of air and fluid leakage from the old PEG site on coughing. She was treated with antibiotics, but when the fistula failed to heal she underwent endoscopy in an attempt to close the fistula using clips. On endoscopy, a large opening on the body of the stomach was seen (Figure [ 1 ]), and five Olympus HX-600-135 clips were deployed internally on the fistula, using an Olympus GIF Q200 gastroscope. Closure was ascertained by air insufflation, which did not demonstrate leakage of air externally. On follow-up the fistula had completely healed (Figure [ 2 ]). Figure 1 Endoscopic appearance of the fistula. Figure 2 The healed fistula following endoscopic clipping. A permanent gastrocutaneous fistula is a rare complication of PEG tube removal. Persistently leaking fistulas usually require surgical closure. However there have been other reports of successful nonsurgical treatment for enterocutaneous fistulas. Shandy et al. [ 1 ] described the use of endoscopically injected fibrin sealant to close a gastrocutaneous fistula, and there are reports on the use of collagen plugs and Gelfoam pledgets [ 2 ] [ 3 ] [ 4 ]. Our patient had a PEG tube in place for 5 years, a persistent cough, and a number of local infections at the PEG site. Although she suffered from psoriasis, there is no evidence to suggest that psoriasis delays wound healing [ 5 ]. The most likely reason for the nonhealing of the fistula in this patient would be the presence of the cough, which mechanically disrupted plug formation. The successful management using clips endoscopically makes the case unique. Endoscopy_UCTN_Code_TTT_1AO_2AI Endoscopy_UCTN_Code_CPL_1AH_2AI
- 1 September 2004
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 36 (9) , 834
Endoscopic Clipping of a Nonhealing Gastrocutaneous Fistula Following Gastrostomy Removal
A 67-year-old lady with anorexia had a percutaneous endoscopic gastrostomy (PEG) tube for long-term feeding. She also suffered from psoriasis. After 5 years the PEG was removed, but a month later she presented at the hospital with a productive cough and symptoms of air and fluid leakage from the old PEG site on coughing. She was treated with antibiotics, but when the fistula failed to heal she underwent endoscopy in an attempt to close the fistula using clips. On endoscopy, a large opening on the body of the stomach was seen (Figure [ 1 ]), and five Olympus HX-600-135 clips were deployed internally on the fistula, using an Olympus GIF Q200 gastroscope. Closure was ascertained by air insufflation, which did not demonstrate leakage of air externally. On follow-up the fistula had completely healed (Figure [ 2 ]). Figure 1 Endoscopic appearance of the fistula. Figure 2 The healed fistula following endoscopic clipping. A permanent gastrocutaneous fistula is a rare complication of PEG tube removal. Persistently leaking fistulas usually require surgical closure. However there have been other reports of successful nonsurgical treatment for enterocutaneous fistulas. Shandy et al. [ 1 ] described the use of endoscopically injected fibrin sealant to close a gastrocutaneous fistula, and there are reports on the use of collagen plugs and Gelfoam pledgets [ 2 ] [ 3 ] [ 4 ]. Our patient had a PEG tube in place for 5 years, a persistent cough, and a number of local infections at the PEG site. Although she suffered from psoriasis, there is no evidence to suggest that psoriasis delays wound healing [ 5 ]. The most likely reason for the nonhealing of the fistula in this patient would be the presence of the cough, which mechanically disrupted plug formation. The successful management using clips endoscopically makes the case unique. Endoscopy_UCTN_Code_TTT_1AO_2AI Endoscopy_UCTN_Code_CPL_1AH_2AI
- Open Access
- 1 December 1999
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 12 (4) , 258-263
Endosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe*
Endoscopic ultrasound of esophageal carcinoma is conventionally performed using the 13-mm fiberoptic/ultrasound echoendoscope. However, the large diameter results in an inability to negotiate the primary tumor in 25% of patients. The aim of this study was first to determine whether use of the 8-mm esophagoprobe would overcome this problem and second to evaluate the accuracy of the smaller diameter instrument. One hundred consecutive patients with esophageal cancer underwent initial gastroscopy. Based upon the degree of luminal stenosis, patients were staged with either the conventional echoendoscope (luminal diameter ≥15 mm) or the esophagoprobe (luminal diameter <15 mm). The primary tumor was successfully negotiated in all subjects (echoendoscope 30, esophagoprobe 70) so that T- and N-staging was accomplished in every patient. Esophageal dilatation was performed in 12 patients (12%). The procedure was well tolerated and there were no complications, in particular no patient suffered esophageal perforation. The accuracy of the esophagoprobe for T-staging was 90% (19 out of 20) and that for N-staging was 75% (15 out of 20). This was similar to the accuracy of staging with the conventional echoendoscope, 90% (9 out of 10) for T-stage and 90% (9 out of 10) for N-stage. The esophagoprobe can safely and accurately stage patients with esophageal carcinoma, including those with high-grade stenoses.
- 1 December 1999
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 12 (4) , 258-263
Open AccessEndosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe*
Endoscopic ultrasound of esophageal carcinoma is conventionally performed using the 13-mm fiberoptic/ultrasound echoendoscope. However, the large diameter results in an inability to negotiate the primary tumor in 25% of patients. The aim of this study was first to determine whether use of the 8-mm esophagoprobe would overcome this problem and second to evaluate the accuracy of the smaller diameter instrument. One hundred consecutive patients with esophageal cancer underwent initial gastroscopy. Based upon the degree of luminal stenosis, patients were staged with either the conventional echoendoscope (luminal diameter ≥15 mm) or the esophagoprobe (luminal diameter <15 mm). The primary tumor was successfully negotiated in all subjects (echoendoscope 30, esophagoprobe 70) so that T- and N-staging was accomplished in every patient. Esophageal dilatation was performed in 12 patients (12%). The procedure was well tolerated and there were no complications, in particular no patient suffered esophageal perforation. The accuracy of the esophagoprobe for T-staging was 90% (19 out of 20) and that for N-staging was 75% (15 out of 20). This was similar to the accuracy of staging with the conventional echoendoscope, 90% (9 out of 10) for T-stage and 90% (9 out of 10) for N-stage. The esophagoprobe can safely and accurately stage patients with esophageal carcinoma, including those with high-grade stenoses.